BKM120

Artikelnummer	Größe	Datenblatt	Manual	SDB	Lieferzeit	Menge	Preis
LKT-B4248.1	1 mg		-		3 - 8 Werktage*		114,00 €
LKT-B4248.5	5 mg		-		3 - 8 Werktage*		316,00 €

Bei Fragen nutzen Sie gerne unser Kontaktformular.
Bestellen Sie auch per E-Mail: info@biomol.com
Größere Menge gewünscht? Bulk-Anfrage

BKM120 is an inhibitor of PI3K that is currently in clinical trials as a potential treatment for... mehr

Menü schließen

Produktinformationen "BKM120"

BKM120 is an inhibitor of PI3K that is currently in clinical trials as a potential treatment for brain metastases of HER2+ breast cancer and other solid tumors. BKM120 exhibits anticancer chemotherapeutic activity, inducing G2/M phase cell cycle arrest, polyploidy, and apoptosis in glioblastoma cells. Additionally, BKM120 decreases levels of Mcl-1 and enhances TRAIL-dependent apoptosis in lung cancer cells. BKM also binds tubulin, inhibiting microtubule polymerization.

Schlagworte:	Buparlisib, NVP-BKM120
Hersteller:	LKT Laboratories
Hersteller-Nr:	B4248

Eigenschaften

Anwendung:	PI3K p110 inhibitor
MW:	410.39 D
Reinheit:	>98%
Format:	Solid

Datenbank Information

CAS :	944396-07-0\| Passende Produkte
KEGG ID :	K00922 \| Passende Produkte

Handhabung & Sicherheit

Lagerung:	+4°C
Versand:	+4°C (International: +4°C)
Signalwort:	Danger
GHS-Piktogramme:
H-Sätze:	H301, H341, H372
P-Sätze:	P201, P202, P260, P264, P270, P281, P301+P310, P308+P313, P314, P321, P330, P405, P501